Product Description
A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/amonafide)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Antisoma Research
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Acute Myeloid Leukemia|Breast Cancer|Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01066494 |
AS1413-C-101 | P2 |
Unknown status |
Acute Myeloid Leukemia |
2010-09-01 |
2019-03-19 |
Treatments |
|
NCT00087854 |
AIPC | P2 |
Completed |
Prostate Cancer |
2005-12-01 |
2019-03-21 |
||
NCT00273884 |
0001A3-200-GL | P2 |
Completed |
Acute Myeloid Leukemia |
None |
2019-03-21 |
Treatments |
|
NCT00074100 |
Amonafide | P2 |
Completed |
Breast Cancer |
None |
2019-03-21 |
Treatments |
|
2007-004427-38 |
ACCEDE | P3 |
Terminated |
Acute Myeloid Leukemia |
2011-01-31 |
2022-03-12 |
Treatments |
|
NCT00715637 |
NCT00715637 | P3 |
Unknown status |
Acute Myeloid Leukemia |
2010-06-01 |
2024-11-27 |
Primary Endpoints |